A detailed history of China Universal Asset Management Co., Ltd. transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 3,163 shares of ARCT stock, worth $80,593. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,163
Previous 5,153 38.62%
Holding current value
$80,593
Previous $174,000 55.75%
% of portfolio
0.01%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$24.35 - $44.39 $48,456 - $88,336
-1,990 Reduced 38.62%
3,163 $77,000
Q1 2024

Apr 29, 2024

BUY
$31.23 - $42.99 $64,458 - $88,731
2,064 Added 66.82%
5,153 $174,000
Q4 2023

May 21, 2024

SELL
$17.71 - $32.97 $36,553 - $68,050
-2,064 Reduced 40.05%
3,089 $97,000
Q4 2023

Jan 23, 2024

BUY
$17.71 - $32.97 $42,610 - $79,325
2,406 Added 352.27%
3,089 $97,000
Q3 2023

May 21, 2024

BUY
$25.44 - $37.35 $8,522 - $12,512
335 Added 96.26%
683 $17,000
Q3 2023

Oct 30, 2023

BUY
$25.44 - $37.35 $8,522 - $12,512
335 Added 96.26%
683 $17,000
Q2 2023

May 21, 2024

SELL
$23.94 - $32.36 $287 - $388
-12 Reduced 3.33%
348 $9,000
Q2 2023

Jul 27, 2023

SELL
$23.94 - $32.36 $287 - $388
-12 Reduced 3.33%
348 $10,000
Q1 2023

May 21, 2024

BUY
$14.72 - $23.97 $1,339 - $2,181
91 Added 33.83%
360 $8,000
Q1 2023

Apr 27, 2023

BUY
$14.72 - $23.97 $1,339 - $2,181
91 Added 33.83%
360 $9,000
Q4 2022

May 21, 2024

SELL
$14.14 - $23.06 $69,059 - $112,625
-4,884 Reduced 94.78%
269 $4,000
Q4 2022

Jan 31, 2023

BUY
$14.14 - $23.06 $282 - $461
20 Added 8.03%
269 $5,000
Q3 2022

Oct 21, 2022

BUY
$13.05 - $22.13 $3,249 - $5,510
249 New
249 $4,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $677M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.